285986-88-1

Basic information

• Product Name: CCG-1423
• Synonyms: CCG-1423;N-(2-(4-Chloroanilino)-1-Methyl-2-oxoethoxy)-3,5-bis(trifluoroMethyl)benzaMide;N-(1-(4-chlorophenylaMino)-1-oxopropan-2-yloxy)-3,5-bis(trifluoroMethyl)benzaMide;N-({1-[(4-Chlorophenyl)Amino]-1-Oxo-2-Propanyl}Oxy)-3,5-Bis(Trifluoromethyl)Benzamide CCG-1423;N-[2-[(4-Chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)-benzamide;N-[1-(4-chloroanilino)-1-oxopropan-2-yl]oxy-3,5-bis(trifluoromethyl)benzamide;Rho/SRF Pathway Inhibitor, CCG-1423
• CAS NO: 285986-88-1
• Molecular Formula: C18H13ClF6N2O3
• Molecular Weight: 454.7508392
• Product Categories: Inhibitors
• Mol File: 285986-88-1.mol
• Article Data: 0

Chemical Properties

• Appearance: white to beige/
• Storage Temp.: 2-8°C
• Solubility: DMSO: soluble5mg/mL, clear (warmed)
• CAS DataBase Reference: CCG-1423(CAS DataBase Reference)
• NIST Chemistry Reference: CCG-1423(285986-88-1)
• EPA Substance Registry System: CCG-1423(285986-88-1)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 285986-88-1(Hazardous Substances Data)

Usage

Description

CCG-1423 is a specific RhoA pathway inhibitor that functions by inhibiting SRF-mediated transcription, a process that has been implicated in both cancer and fibrosis. CCG-1423 has the potential to be a valuable tool in the development of therapeutic strategies for these conditions.

Uses

Used in Pharmaceutical Industry:
CCG-1423 is used as a therapeutic agent for the treatment of cancer and fibrosis due to its ability to inhibit the RhoA pathway and SRF-mediated transcription, which are involved in the development and progression of these diseases.
Used in Research Applications:
CCG-1423 is used as a research tool to study the role of the RhoA pathway and SRF-mediated transcription in cancer and fibrosis. CCG-1423 can help researchers better understand the molecular mechanisms underlying these conditions and identify potential targets for therapeutic intervention.
Used in Drug Development:
CCG-1423 is used in the development of new drugs targeting the RhoA pathway and SRF-mediated transcription, with the aim of creating more effective treatments for cancer and fibrosis. Its specificity for the RhoA pathway makes it a promising candidate for the development of targeted therapies with fewer side effects.